Neuraxpharm Buccolam Acquisition Opens Up Opportunities
Strikes Deal With Takeda For The Only Buccal Midazolam Approved Across Europe
Executive Summary
Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.
You may also be interested in...
Neuraxpharm Expands In Switzerland With New Local Head
Neuraxpharm has appointed Jörg Gärtner to lead its business in Switzerland, as the CNS specialist prepares to roll out its medical cannabis portfolio in the region.
Neuraxpharm’s Brain Acquisition Stems From Expansion Ambitions
Privately-owned Neuraxpharm has found another company to give it further access to a new European market, picking up Athens-based Brain Therapeutics. It aims now to introduce its Buccolam (midazolam) in Greece.
Neuraxpharm Expands Into The Nordics With New Leader From Viatris
In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam.